多模态策略评估心血管风险:两项人群队列中的表现
在无已知心血管病的成人中,联合心电图左心室肥厚、冠状动脉钙化、NT-proBNP、hs-cTnT和hs-CRP五种检测可改善全局心血管病和动脉粥样硬化性心血管病风险评价;异常项计数评分越高,风险逐级升高,结果在 Dallas 心脏研究中得到重复。
要点
- 五种检测联合基础模型使全局CVD的c统计量从0.74升至0.79(P=0.001)。
- 异常检测项计数评分1、2、3、≥4的全局CVD调整HR分别为1.9、3.2、4.7、7.5。
- 在Dallas心脏研究中,该策略对ASCVD结局的发现相似。
核心结论
- 在无已知CVD的成人中,联合心电图左心室肥厚、冠状动脉钙化、NT-proBNP、hs-cTnT和hs-CRP的多模态检测策略显著改善了全局CVD和ASCVD风险评价。
研究设计与样本
- 研究纳入MESA队列6621名和Dallas心脏研究2202名无CVD的参与者,随访超过10年。
主要发现
- 在MESA中,校正基础模型组分和其他检测结果后,每种检测结果均独立与全局复合CVD事件相关(每项P<0.05)。
- 将5种检测加入基础模型后,c统计量从0.74提高至0.79(P=0.001),综合判别改善指数为0.07(95%CI 0.06-0.08,P<0.001),类别无净重分类改善为0.47(95%CI 0.38-0.56,P=0.003),模型校准良好(χ2=12.2,P=0.20)。
- 采用计算异常检测项数的简单整数评分,与评分为0者相比,评分为1者的全局CVD调整风险比为1.9(95%CI 1.4-2.6),评分为2者为3.2(95%CI 2.3-4.4),评分为3者为4.7(95%CI 3.4-6.5),评分≥4者为7.5(95%CI 5.2-10.6)。
- 在Dallas心脏研究中,该策略对ASCVD结局的发现相似。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current strategies for cardiovascular disease (CVD) risk assessment among adults without known CVD are limited by suboptimal performance and a narrow focus on only atherosclerotic CVD (ASCVD). We hypothesized that a strategy combining promising biomarkers across multiple different testing modalities would improve global and atherosclerotic CVD risk assessment among individuals without known CVD. METHODS: We included participants from MESA (Multi-Ethnic Study of Atherosclerosis) (n=6621) and the Dallas Heart Study (n=2202) who were free from CVD and underwent measurement of left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein. Associations of test results with the global composite CVD outcome (CVD death, myocardial infarction, stroke, coronary or peripheral revascularization, incident heart failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocardial infarction or stroke) were assessed over >10 years of follow-up. Multivariable analyses for the primary global CVD end point adjusted for traditional risk factors plus statin use and creatinine (base model). RESULTS: Each test result was independently associated with global composite CVD events in MESA after adjustment for the components of the base model and the other test results (P<0.05 for each). When the 5 tests were added to the base model, the c-statistic improved from 0.74 to 0.79 (P=0.001), significant integrated discrimination improvement (0.07, 95% confidence interval [CI] 0.06-0.08, P<0.001) and category free net reclassification improvement (0.47; 95% CI, 0.38-0.56; P=0.003) were observed, and the model was well calibrated (χ2=12.2, P=0.20). Using a simple integer score counting the number of abnormal tests, compared with those with a score of 0, global CVD risk was increased among participants with a score of 1 (adjusted hazard ratio, 1.9; 95% CI, 1.4-2.6), 2 (hazard ratio, 3.2; 95% CI, 2.3-4.4), 3 (hazard ratio, 4.7; 95% CI, 3.4-6.5), and ≥4 (hazard ratio, 7.5; 95% CI, 5.2-10.6). Findings replicated in the Dallas Health Study were similar for the ASCVD outcome. CONCLUSIONS: Among adults without known CVD, a novel multimodality testing strategy using left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein significantly improved global CVD and ASCVD risk assessment.
引用
- de Lemos JA, Ayers CR, Levine BD, et al. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. Circulation. 2017. PMID: 28360032. doi:10.1161/CIRCULATIONAHA.117.027272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。